New hope for tough breast cancer: experimental drug trial seeks to slow disease progression
NCT ID NCT07299409
Summary
This study is testing whether the drug sacituzumab govitecan can slow cancer progression when used as the first treatment for advanced triple-negative breast cancer. Researchers will enroll 24 adults who haven't received prior treatment for their advanced cancer and give them the drug in 21-day cycles. The study will also check if the drug works differently based on specific genetic features of each person's cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BC Cancer - Vancouver Center
Vancouver, British Columbia, V5Z 4E6, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.